BMS, the American pharmaceutical firm, reached agreements with several generic companies to distribute restricted quantities of generic Revlimid in the US beginning March 2022.
BMS, the American pharmaceutical firm, reached agreements with several generic companies to distribute restricted quantities of generic Revlimid in the US beginning March 2022.